Biography

Frank W. Mullery serves as President and Chief Executive Officer of Harrow’s ImprimisRx Division. With over 20 years of leadership experience in the healthcare and pharmaceutical sectors, he has built and scaled businesses, launched market-shaping products, and driven transformative growth. Most recently, he served as President of Sintetica US, where he spearheaded the creation of the company’s U.S subsidiary – taking it from concept to full commercialization, while successfully launching its first five sterile injectable products. Previously, he served as President and Chief Commercial Officer of STI Pharma, where he oversaw all company operations, revitalized its strategy with a five-year growth plan, and launched several sterile injectable products. Prior to STI, he spent more than seven years at Mylan, culminating in his role as President of Mylan Institutional, where he established Mylan Institutional as a key player in the U.S. sterile injectable market. Under his leadership, revenues grew to more than $1 billion in 2018, launched its first U.S. biosimilar (Fulphila), introduced over 20 sterile injectable products in a single year, and established strong relationships with key customers. Mr. Mullery also held senior finance leadership roles at Mylan, including CFO of North America and CFO of Mylan Pharmaceuticals Inc., where he helped guide the company’s flagship generics division. He holds an Executive MBA from Villanova University and a bachelor’s degree in Accounting from King’s College.